Colorectal Cancer After Start of Nonsteroidal Anti-Inflammatory Drug Use

American Journal of Medicine

Volumn 119, Issue 6, 2006, Pages 494-502

  Stürmer, Til ^a   Buring, Julie E ^a,b,c   Lee, I Min ^a,c   Kurth, Tobias ^a,c   Gaziano, J Michael ^a,d   Glynn, Robert J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti inflammatory agents, Nonsteroidal; Chemoprevention; Colorectal neoplasms; Confounding factors (epidemiology); Epidemiology; Pharmacoepidemiology; Selection bias

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTHRITIS; ARTICLE; BODY MASS; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NORMAL HUMAN; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK REDUCTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHYSICIANS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SELECTION BIAS; SELF MEDICATION; TIME FACTORS; UNITED STATES;

EID: 33646943234     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.11.011     Document Type: Article

References (31)

1. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents. mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
2. Janne P.A., and Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 342 (2000) 1960-1968
3. Asano T.K., and McLeod R.S. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer. a systematic review. Dis Colon Rectum 47 (2004) 665-673
4. Chan T.A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon cancer chemoprevention. Lancet Oncol 3 (2002) 166-174
5. Rigas B., and Shiff S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAID in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54 (2000) 210-215
6. Chan A.T. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia. future challenges in chemoprevention. Cancer Causes Control 14 (2003) 413-418
7. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
8. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
9. Gann P.H., Manson J.E., Glynn R.J., Buring J.E., and Hennekens C.H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85 (1993) 1220-1224
10. Stürmer T., Glynn R.J., Lee I.-M., Manson J.E., Buring J.E., and Hennekens C.H. Aspirin use and colorectal cancer. post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128 (1998) 713-720
11. Cook N.R., Lee I.M., Gaziano J.M., et al. Low-dose aspirin in the primary prevention of cancer. The Women's Health Study: a randomized controlled trial. JAMA 294 (2005) 47-55
12. Michels K.B., and Braunwald E. Estimating treatment effects from observational data. Dissonant and resonant notes from the SYMPHONY trials. JAMA 287 (2002) 3130-3132
13. Ray W. Evaluating medication effects outside of clinical trials. new-user designs. Am J Epidemiol 158 (2003) 915-920
14. Manson J.E., Buring J.E., Satterfield S., and Hennekens C.H. Baseline characteristics of participants in the Physicians' Health Study. a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med 7 (1991) 150-154
15. Steering Committee of the Physicians' Health Study Research Group. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
16. Christen W.G., Gaziano J.M., Hennekens C.H., and Steering Committee Of Physicians' Health Study II. Design of Physicians' Health Study II. a randomized trial of beta-carotene, vitamin E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10 (2000) 125-134
17. Zeger S.L., Liang K.Y., and Albert P.S. Models for longitudinal data. a generalized estimating equation approach. Biometrics 44 (1988) 1049-1060
18. Anderson P.K., and Gill R.D. Cox's regression model for counting processes. a large sample study. Ann Stat 10 (1992) 1100-1120
19. Stürmer T., Schneeweiss S., Brookhart M.A., Rothman K.J., Avorn J., and Glynn R.J. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores. nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 161 (2005) 891-898
20. Giovannucci E., Egan K.M., Hunter D.J., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333 (1995) 609-614
21. Collet J.P., Sharpe C., Belzile E., Boivin J.F., Hanley J., and Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs. effects of dosage and timing. Br J Cancer 81 (1999) 62-68
22. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Stolley P.D., and Shapiro S. A hypothesis. nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83 (1991) 355-358
23. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs. the relationships among dose, effectiveness, and side effects. Chest 119 Suppl (2001) 39S-63S
24. Kune G.A., Kune S., and Watson L.F. Colorectal cancer risk, chronic illnesses, operations, and medications. case control results from the Melbourne colorectal cancer study. Cancer Res 48 (1988) 4399-4404
25. Muller A., Sonnenberg A., and Wasserman I.H. Diseases preceding colorectal cancer. a case-control study among veterans. Dig Dis Sci 39 (1994) 2480-2484
26. Baron J.A., and Adami H.O. A broad anticancer effect of aspirin? Editorial. Epidemiology 5 (1994) 133-135
27. McDermott M.M., Schmitt B., and Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 157 (1997) 1921-1929
28. Sesso H.D., Gaziano J.M., VanDenburgh M., Hennekens C.H., Glynn R.J., and Buring J.E. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial. the Physicians' Health Study. Control Clin Trials 23 (2002) 686-702
29. Chan A.T., Giovannucci E.L., Schernhammer E.S., et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140 (2004) 157-166
30. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Curhan G.C., and Fuchs C.S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294 (2005) 914-923
31. Reddy B.S., Hirose Y., Lubet R., et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60 (2000) 293-297